May 6, 2013
Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds
February 26, 2013
Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate
February 19, 2013
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease
Concert walked in the NKF’s Boston Walk to help raise kidney disease awareness.
Concert uses deuterium-based chemistry to create and develop highly differentiated new medicines by leveraging decades of pharmaceutical and clinical experience to reduce time, risk and expense.
Concert in the
news... a selection of news stories featuring Concert.
With the innovation of implementing deuterium, Concert Pharmaceuticals Inc. is demonstrating itself a pioneer in the world of science. Read more
Issued U.S. Patents
Concert is building a broad patent estate. View List
Concert will present at the Wells Fargo Healthcare Conference on June 18, 2013 in Boston.
Business Development/Strategic Partnering
Concert will present at the Translational CNS Summit taking place May 21-23, 2013 in Boston.